The tulip mania is on! How easily the gullible are duped with manufactured good news. Had anybody expected any different news than the experiment had worked perfectly and the cure is there already? Fools!
A free public upgrade! Is it worth anything except they want their clients or insiders to unload their holdings? Who are they kidding with? When did JP Morgan become such a charitable organization?
Obviously, you done very well. What I see is that many others are doing the CART too. And, we simply do not know who will make it through. Ariad has been a dog for last twenty years and no pharma wants to buy it. I would trade this stock but never go long unless you got some good cushion. This could be 10 dollar or 100 dollar stock. I would be on the sideline until I see some tangible results. I am not in hurry. There will be plenty of chance to get in. I have been holding GILD since year 2004 and never been disappointed. I do my home work rigorously. I would not go for hot air as many went for genomics in the past.
This can't be a standalone company like ILMN. It has to go belly up or be taken over by another company with money. Helicos is the fate here.
Ask yourself whether this will make or burn money for next five years? This is a pure gamble at this point. It requires a deep pocket to take it to somewhere? Five years is simply too long for cancer sufferers.
You probably do not even why you bought the stock in first place. Based on Mad money fundamentals, I suppose?
I would not touch these CART companies until the dust settles. Clinical trials need to be moved forward beyond phase II before we know that the technology is real and safe? It would retrace the IPO price again.
The bottom line here whether a unknown technology should fetch 4B dollar market cap? This company is 5 to 7 years away from a real product and people are hyping it as if no other company would catch up with the company by slightly modifying the method. If it comes down to 35, the panic will set in. I would sell now and wait for better price. I do mot see any new news from ASCO conference. Trust me, in Biology, things move very slowly..
25-30 would be my price and for new money! There are simply too many unknown hurdles this company has to manage before it takes off or go down as a fluke. Right now, the technology is pure gamble. Shorts would do a great favor taking it down to the 25 level. Good luck!
Which Genomic company did really shine so far? Millenium did not have a product until they bought Velcade rights...developed by another company. Tell me how do you design a drug based on a single mutation or multiple mutations. Answer me if you care. I bet, you are not familiar with science. Yes, sequencing can detect somatic mutations in certain tissue DNAs but then what?
Personalized medicine is a total BS. Most of the genomic DNA is just junk. If you find a mutation in the introns, that may not give you any clue, let alone a personalized medicine. Moreover, most the diseases are multi-factoral or environmental. Personalized medicine would not be much help. It is rather a sexy word for grant money.
Of course it should work. But that is not the question. Can it survive the ruthless competition from the Goliath? It will see meet a slow death. Mark my word!
So, if TSLA is OK, JUNO should be OK too with 4B tag? Could you please tell me where did you get your academic degree? You really got a lethal logic for Juno!